Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects

Jason Charles Ray, Mahima Kapoor, Richard J Stark, Shuu-Jiun Wang, Lars Bendtsen, Manjit Matharu, Elspeth Jane Hutton

29 Citationer (Scopus)

Abstract

Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.

OriginalsprogEngelsk
Artikelnummer324674
TidsskriftJournal of neurology, neurosurgery, and psychiatry
Vol/bind92
Udgave nummer12
Sider (fra-til)1325-1334
Antal sider10
ISSN0022-3050
DOI
StatusUdgivet - dec. 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects'. Sammen danner de et unikt fingeraftryk.

Citationsformater